Discussion on Strengthening Financial Supervision of Pharmaceutical Industry under the Background of New Medical Reform

2017 ◽  
Vol 23 (3) ◽  
Author(s):  
Chunjiang Yang ◽  
Xiuli Tan ◽  
Yujiang Yang ◽  
Anqel Chen
Keyword(s):  
Pharmaceutical Industry ◽  
Financial Regulation ◽  
Market Competition ◽  
Living Environment ◽  
Financial Supervision ◽  
Pharmaceutical Companies ◽  
Existing Problems ◽  
Medical Reform ◽  
And Control ◽  
Pharmaceutical Enterprises

Abstract: with the continuous development of the economy and the improvement of the medical technological level, China's pharmaceutical industry is also undergoing sustainable development while the market competition among pharmaceutical companies is being intensified. Leading the operation of pharmaceutical companies and promoting the progress of the pharmaceutical industry, financial regulation is the most important part of many management projects. Hence, strengthening the financial supervision of pharmaceutical companies has become the key to the development of the pharmaceutical industry. However, the financial supervision of domestic pharmaceutical companies under the new medical reform shows many problems, such as poor concept of financial supervision, weak basic supervision, weak budget management and control as well as poor cost control capacity, which make the financial supervision of pharmaceutical enterprises can not proceed smoothly. Therefore, corresponding countermeasures need to be developed. By analyzing the changes of the living environment of domestic pharmaceutical enterprises and the development of financial supervision under the new medical reform, this paper discusses the existing problems in the financial supervision of pharmaceutical enterprises, and puts forward corresponding measures to promote the development of the pharmaceutical industry.

The Impact of Information Systems on Management Performance in the Pharmaceutical Industry

2015 ◽  
Vol 17 (3) ◽  
pp. 56-73 ◽  
Author(s):  
Sherif Elshorbagy ◽  
Lalit Garg ◽  
Vipul Gupta ◽  
Gopalakrishnan Narayanamurthy ◽  
Yosuf Abd Al Oraini
Keyword(s):  
Pharmaceutical Industry ◽  
Pharmaceutical Companies ◽  
Successful Implementation ◽  
Strategic Decisions ◽  
Management Performance ◽  
Business Operations ◽  
Lack Of Information ◽  
Short Time ◽  
And Control ◽  
The Impact

There are many aspects that should be considered while implementing ISs in pharmaceutical companies. This is due to the various regulations and standards that the governmental authorities impose on these companies. In addition, any audit from US Food and Drug Administration (FDA) or other authorities will require computer system validation to be performed for the implemented ISs to ensure that all areas that affect the drugs lifecycle are following the required standards, and that each single process in this lifecycle is validated. Unfortunately, many pharmaceutical companies didn't recognize yet the importance of ISs to their businesses. The research presented in this paper examines the value of using an information system (IS) in pharmaceutical environment and how it can be a key component of improving the operational and process effectiveness by supporting the strategic decisions and enabling the decision-makers to take their decisions in short time. Lack of information in pharmaceutical companies is one of the reasons why these companies will not be able to compete in this competitive market because the delays in taking decisions, product lifecycle, and supply chain. Pharmaceutical companies required to follow various regulations and standards, and ISs are the tools that can be mapped to these standards and control the business operations without any obstacles. The authors conducted a comprehensive study to investigate the role of ISs in the pharmaceutical industry through a review of existing literatures relevant to the research subject and through a questionnaire survey with 54 participants working in the pharmaceutical industry in different countries in the Middle East. The survey aimed to understand the present status of ISs in pharmaceutical companies and the impact of ISs on management performance, operation improvement, end-users productivity, and compliance with the regulations and standards of the pharmaceutical industry in their companies. Moreover, the survey also aimed to identify the catalysts behind successful implementation of ISs.

scholarly journals Patenting and strategies of major pharmaceutical companies in Brazil

2020 ◽  
Vol 9 (9) ◽  
pp. e264996896
Author(s):  
Gláucia Rocha Acioli ◽  
Ana Karla de Souza Abud ◽  
Antonio Martins de Oliveira Júnior
Keyword(s):  
Pharmaceutical Industry ◽  
Intangible Assets ◽  
Market Competition ◽  
Survival Strategies ◽  
Pharmaceutical Companies ◽  
Research Support ◽  
Systematic Analysis ◽  
Strategic Performance ◽  
Patent Applications

Facing the contemporaneous changes which have intensified the market competition, survival strategies are essential for the company sustainability, such as the protection of intangible assets through the patents, which confer several advantages. In the pharmaceutical industry, where the products are result from expensive processes, the patents have become an important incentive. This article has undertaken a systematic analysis of patenting in the Brazilian pharmaceutical industry, evaluating the patents indicators of the major pharmaceutical companies in Brazil in order to categorize their strategies. The results indicated the leadership of Aché in patent applications, an extremely small number of concessions, characterizing the majority of the deposits as Invention Patents, and the lack of partnerships with universities and /or foundations for research support. The EMS and Eurofarma companies have presented analytical strategic performance, the União Química, defender, and Aché and Hypermarcas, prospector performance.

scholarly journals A Measurement System Of Corporate Social Responsibility In The Pharmaceutical Industry Of The Region

2010 ◽  
Vol 14 (5) ◽  
Author(s):  
Neda Vitezic
Keyword(s):  
Corporate Social Responsibility ◽  
Pharmaceutical Industry ◽  
Social Responsibility ◽  
Stakeholder Theory ◽  
Measurement System ◽  
Pharmaceutical Companies ◽  
Pharmaceutical Sector ◽  
Socially Responsible ◽  
Corporate Social ◽  
Pharmaceutical Enterprises

Recently, the concept of Corporate Social Responsibility (CSR) has been adopted by many business sectors in the world including pharmaceutical industry. The orientation to social and environmental issues in business operations became a subject of much different research since the development of the stakeholder theory. The stakeholder theory emphasised social responsibility because a company’s performance and business in general could not be measured solely by gaining profit. Shareholders and managers should be responsible for all others who «directly or indirectly affect or are affected by a firm's activities». Much attention has been devoted to this concept in the researcher’s analysis in a range of sectors, but CSR research has been limited in the pharmaceutical sector. Measurement system is especially insufficiently analysed in relation to outcome measures to overall stakeholders. Thus, the purpose of the research is to analyse pharmaceutical industry in the Region (some of the ex-Yugoslavian countries - today Slovenia, Croatia, Serbia, Bosnia and Herzegovina, Macedonia) which have developed a social responsibility concept in their renowned pharmaceutical enterprises. The research objectives are to investigate the CSR measurement system and make conclusions through critical analysis of the used indicators. The objective is to make a differentiation between pharmaceutical enterprises in using indicators to present economical, environmental and social issues. The final aim is to unify the approach to CSR in the pharmaceutical sector in the Region, as there is no agreement between relevant stakeholders and pharmaceutical industry about socially responsible pharmaceutical companies. The used research methods are: scientific analytical methods, interview, desk research, statistical methods. Research results: based on detailed analysis of the measurement system in the main pharmaceutical companies in four countries in the Region (a total of 12 in the sample) a model of a socially responsible pharmaceutical company is set up.

Economic Patriotism After the Crisis: Explaining Continuity and Change in European Securities Enforcement

2018 ◽  
Author(s):  
Chase Foster
Keyword(s):  
Financial Crisis ◽  
Insider Trading ◽  
Financial Regulation ◽  
Global Financial Crisis ◽  
Financial Supervision ◽  
Financial Centre ◽  
Continuity And Change ◽  
Financial Interests ◽  
Mixed Pattern ◽  
The Uk

Since the global financial crisis, European governments have sought to intensify the supervision of financial markets. Yet, few studies have empirically examined whether regulatory approaches have systematically shifted in the aftermath of the crisis, and how these reforms have been mediated by longstanding national strategies to promote domestic financial interests in the European single market. Examining hundreds of enforcement actions in three key European jurisdictions, I find a mixed pattern of continuity and change in the aftermath of the crisis. In the UK, aggregate monetary penalties and criminal sanctions have skyrocketed since 2009, while in France and Germany, the enforcement pattern suggests continuity, with both countries assessing penalties and prosecuting insider trading at similar rates before and after the crisis. I conclude that financial regulation is still structured by longstanding industrial strategies (Story and Walter, 1997), but where pre-existing regulatory approaches were seen as contributing to the crisis, a broader regulatory overhaul has been pursued. Thus, in the UK, where the financial crisis served as a direct rebuke to the country’s “light touch” regulation, financial supervision was overhauled, and monetary sanctions dramatically increased, to preserve London’s status as an international financial centre. By contrast, in France and Germany, where domestic regulatory systems were implicated by the financial crisis, domestic securities supervision and enforcement was less dramatically altered. While the crisis has led to the further institutionalization of European-level supervisory institutions, these changes have not yet led to convergence in national regulatory approaches.   Full text available at: https://doi.org/10.22215/rera.v12i1.1233

scholarly journals Strategic account management as a value co-creation selling model in the pharmaceutical industry

2017 ◽  
Vol 32 (2) ◽  
pp. 310-325 ◽  
Author(s):  
Francois Pilon ◽  
Elias Hadjielias
Keyword(s):  
Pharmaceutical Industry ◽  
Pharmaceutical Company ◽  
Value Added ◽  
Pharmaceutical Companies ◽  
Design Data ◽  
Content Type ◽  
Qualitative Research Design ◽  
Account Management ◽  
A Value ◽  
Key Accounts

Purpose This study aims to explore the dynamics enabling strategic account management (SAM) to function as a value co-creation selling model in the pharmaceutical industry. Design/methodology/approach Using an inductive qualitative research design, data are collected within 11 industry customers in Canada. This work focuses on hospitals as strategic accounts of pharmaceutical companies, exploring SAM value co-creation in the “hospital-pharmaceutical company” relationship. Findings The findings suggest the presence of two key dimensions that can enable a value co-creation SAM model in the hospital-pharmaceutical relationship: “customer-tailored value-added initiatives” and “relationship enhancers”. Customer-tailored value-added initiatives explain the activities that are central to the hospital-pharmaceutical company relationship and can lead to the provision of value added that is unique to the hospital. Relationship enhancers explain the activities that can help strengthen hospital-pharmaceutical company relations in the pursuit of enhanced value-added interactions between the two parties. The research demonstrates a cyclical relationship between “customer-tailored value-added initiatives” and “relationship enhancers”, leading to value co-creation through a SAM model. Practical implications The study informs pharmaceutical industry practitioners on how to improve their value proposition through new, more sustainable selling practices. It offers information on implementing a value co-creation SAM model, which can enable pharmaceutical companies to sustain long-lasting value-added relationships with key accounts such as hospitals. Originality/value The study contributes to the field of SAM by conceptualizing SAM as a value co-creation system. It introduces new knowledge in pharmaceutical marketing by offering empirical insight on the applicability and use of SAM in the hospital-pharmaceutical company dyad.

Typical Pharmaceutical Process VOCs and Stench Pollution Characteristics and Control Techniques

2013 ◽  
Vol 726-731 ◽  
pp. 2017-2021 ◽  
Author(s):  
Zhao Du ◽  
Xiang Ling Yuan ◽  
Ai Ling Ren ◽  
Feng Ying Fu
Keyword(s):  
Pharmaceutical Industry ◽  
Atmospheric Environment ◽  
Synthesis Process ◽  
Exhaust Gas ◽  
Control Technology ◽  
Environment Pollution ◽  
Control Techniques ◽  
Waste Characteristics ◽  
And Control ◽  
Gas Recycling

According to the pharmaceutical industry produce VOCs and stench of atmospheric environment pollution, combined with typical pharmaceutical biological fermentation and chemical synthesis process of VOCs and odour pollution are classified 4 types:fermentation tail gas, recycling of exhaust gas, exhaust gas and wastewater workshop stench. The control technology should be selected according to the four types of waste characteristics.

The Ethics of Accepting Gifts from Pharmaceutical Companies

PEDIATRICS ◽  
1991 ◽  
Vol 88 (6) ◽  
pp. 1233-1237
Author(s):  
Lewis H. Margolis
Keyword(s):  
Pharmaceutical Industry ◽  
Medical Community ◽  
Pharmaceutical Companies ◽  
Ongoing Debate ◽  
The Subject

How physicians respond to the promotional activities of the pharmaceutical industry is the subject of ongoing debate and controversy. This paper postulates that the acceptance of gifts in virtually any form violates fundamental duties of the physician of nonmaleficence, fidelity, justice, and self-improvement. The medical community must articulate this position clearly, and it should act accordingly.

Sign in / Sign up

Export Citation Format

Share Document